Paul Corn

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein
    Paul G Corn
    Department of Medicine, Howard Hughes Medical Institute and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Genet 35:229-37. 2003
  2. ncbi request reprint Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic cancer [corrected] epigenome
    Paul G Corn
    MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1157-9. 2008
  3. pmc The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
    Paul G Corn
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
    Cancer Manag Res 4:183-93. 2012
  4. pmc Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials
    A Som
    Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77230, USA
    Br J Cancer 107:1547-53. 2012
  5. pmc Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study
    Paul G Corn
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 86:540-5. 2013
  6. ncbi request reprint Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage
    Paul G Corn
    MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Biol Ther 6:1858-66. 2007
  7. ncbi request reprint Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence
    Paul G Corn
    MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, Texas 77030, USA
    Cancer Biol Ther 7:265-7. 2008
  8. doi request reprint Novel therapies for metastatic castrate-resistant prostate cancer
    Farshid Dayyani
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 103:1665-75. 2011
  9. pmc Role of the ubiquitin proteasome system in renal cell carcinoma
    Paul G Corn
    MD Anderson Cancer Center, GU Medical Oncology, Box 1374, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    BMC Biochem 8:S4. 2007
  10. ncbi request reprint Reactivation of p53 function with a demethylating agent
    Paul G Corn
    MD Anderson Cancer Center, Genitourinary Medical Oncology Department, Houston, Texas 77030, USA
    Cancer Biol Ther 5:1161-2. 2006

Research Grants

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein
    Paul G Corn
    Department of Medicine, Howard Hughes Medical Institute and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Genet 35:229-37. 2003
    ..Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors...
  2. ncbi request reprint Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic cancer [corrected] epigenome
    Paul G Corn
    MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1157-9. 2008
  3. pmc The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
    Paul G Corn
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
    Cancer Manag Res 4:183-93. 2012
    ..An improved understanding of the complex relationship between cancer epithelial cells and the organ-specific microenvironments with which they interact has created a powerful opportunity to develop novel therapies...
  4. pmc Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials
    A Som
    Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Houston, TX 77230, USA
    Br J Cancer 107:1547-53. 2012
    ....
  5. pmc Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study
    Paul G Corn
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 86:540-5. 2013
    ..To evaluate the feasibility of administering sunitinib in combination with androgen deprivation therapy and external-beam intensity modulated radiation therapy (XRT) in patients with localized high-risk prostate cancer...
  6. ncbi request reprint Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage
    Paul G Corn
    MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Biol Ther 6:1858-66. 2007
    ..These data suggest a hypothesis that the combination of hypoxia and DNA damage promotes resistance to therapy by eliciting a transcriptional response that favors cell cycle arrest over apoptosis...
  7. ncbi request reprint Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence
    Paul G Corn
    MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, Texas 77030, USA
    Cancer Biol Ther 7:265-7. 2008
  8. doi request reprint Novel therapies for metastatic castrate-resistant prostate cancer
    Farshid Dayyani
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 103:1665-75. 2011
    ..The rationale to disrupt this "two-compartment" crosstalk has led to the development of drugs that target tumor stromal elements in addition to the cancer epithelial cell...
  9. pmc Role of the ubiquitin proteasome system in renal cell carcinoma
    Paul G Corn
    MD Anderson Cancer Center, GU Medical Oncology, Box 1374, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    BMC Biochem 8:S4. 2007
    ..Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com)...
  10. ncbi request reprint Reactivation of p53 function with a demethylating agent
    Paul G Corn
    MD Anderson Cancer Center, Genitourinary Medical Oncology Department, Houston, Texas 77030, USA
    Cancer Biol Ther 5:1161-2. 2006
  11. pmc Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes
    Bradley J Atkinson
    Department of Pharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 113:376-82. 2014
    ..To characterise the incidence, onset, management, predictors, and clinical impact of mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis (NIP) on patients with metastatic renal cell carcinoma (mRCC)...
  12. pmc Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules
    Bradley J Atkinson
    Department of Pharmacy Clinical Programs, University of Texas M D Anderson Cancer Center, Houston, Texas
    J Urol 191:611-8. 2014
    ..We identified sunitinib alternative schedules that maintained dose intensity while decreasing adverse events in patients with metastatic renal cell cancer. We also determined the impact of alternative schedules on clinical outcomes...
  13. pmc Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation
    John C Araujo
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2153-9. 2009
    ..Since Src kinase has been shown to be necessary for osteoclast function, we hypothesized that dasatinib, a Src family kinase inhibitor, would reduce osteoclast activity and prostate cancer (PC-3) cell-induced osteoclast formation...
  14. ncbi request reprint The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan
    Guiyun Song
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 55:1625-34. 2014
    ..These results provide a mechanistic basis for using SAHA in future clinical trials with double nucleoside analog-busulfan combinations in pretransplant conditioning therapy...
  15. ncbi request reprint Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    ..The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC)...
  16. ncbi request reprint Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
    ....
  17. pmc Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity
    Abujiang Pataer
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biol Ther 8:245-52. 2009
    ..Our results suggest a rationale to develop therapeutic strategies that target PKR signaling in human cancer cells...
  18. ncbi request reprint Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis
    Chun Chui Tsao
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1619-27. 2008
    ..Compared to Mxi1-proficient tumors, Mxi1-deficient tumors display reduced cellular proliferation. These results establish Mxi1 as an important downstream target of HIF that contributes to pVHL-deficient renal cancer tumorigenesis...
  19. pmc 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 34:364-72. 2010
    ..Our results suggest that, depending on tumor p53 status, incorporation of DAC might synergistically improve the cytoreductive efficacy of Bu-based pretransplant regimen in patients with ML...
  20. ncbi request reprint Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer
    Paul G Corn
    University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Carcinogenesis 24:47-51. 2003
    ..These results suggest that epigenetic inactivation of Chfr may be responsible for many of the checkpoint defects observed in human cancers...
  21. ncbi request reprint Caspase 10 levels are increased following DNA damage in a p53-dependent manner
    Bart Rikhof
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Departments of Medicine, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 2:707-12. 2003
    ..Upregulation of caspase 10 may represent one factor that determines how p53 activation leads to cellular apoptosis following DNA damage...
  22. ncbi request reprint Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis
    Paul G Corn
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 4:1285-94. 2005
    ..The results suggest a coordinated mechanism for opposing c-Myc signaling during hypoxia that is mediated by a reduction in c-Myc levels, the induction of Mxi1, and a dominant effect of HIF-1 transcriptional activity...
  23. ncbi request reprint Hypoxic regulation of mRNA expression
    Lawrence B Gardner
    New York University School of Medicine and MD Anderson Cancer Center, USA
    Cell Cycle 7:1916-24. 2008
    ..Recent data from our laboratory demonstrate that nonsense mediated RNA decay is also regulated in hypoxic cells and thus may play an important role in hypoxic gene regulation and hypoxic phenotypes...
  24. ncbi request reprint Derangement of growth and differentiation control in oncogenesis
    Paul G Corn
    Department of Medicine, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Bioessays 24:83-90. 2002
    ..Insights into what distinguishes the regulation of growth and differentiation in a normal cell versus a cancer cell have led to the development of novel anticancer therapies...

Research Grants1

  1. Regulation of the von Hippel-Lindau Protein
    Paul Corn; Fiscal Year: 2007
    ..abstract_text> ..